Article Sidebar

PDF
Date Published: 05/01/2022
Abstract Views: 822
Views PDF: 504
DOI: https://doi.org/10.51298/vmj.v508i1.1579
Issue
Vol. 508 No. 1 (2021)
Section
Các bài báo
How to Cite
Hồng Thịnh, L. ., Đình Tới, C. ., & Hải Bình, B. . (2022). CURRENT STATUS OF BIOLOGICAL TREATMENT IN RHEUMATOID ARTHRITIS PATIENT AT THE DEPARTMENT OF RHEUMATOLOGY – BACH MAI HOSPITAL. Vietnam Medical Journal, 508(1). https://doi.org/10.51298/vmj.v508i1.1579

CURRENT STATUS OF BIOLOGICAL TREATMENT IN RHEUMATOID ARTHRITIS PATIENT AT THE DEPARTMENT OF RHEUMATOLOGY – BACH MAI HOSPITAL

Lại Hồng Thịnh1,, Chu Đình Tới2, Bùi Hải Bình3
1 Ha Nam General Hospital
2 ietnam National University, Hanoi
3 Bach Mai Hospital

Main Article Content

Abstract

Objectives: Describe the current status of using biological drugs in the treatment of rheumatoid arthritis patients at the Department of Rheumatology - Bach Mai Hospital and identify some influencing factors. Subjects and methods: A prospective cross-sectional descriptive study combined with a retrospective on 71 rheumatoid arthritis patients receiving biologic drugs at the study site from January 2017 to December 2020. Results: The first-line bDMARD of choice was IL-6 inhibitor (83.1%), 29.1% of patients switching to the second biologic drug (the most common being TNF inhibitor), The maintenance time of the IL-6 inhibitor group was 131 weeks (CI95%: 108,2-153,8), of the TNF inhibitor group was 46 weeks (CI95%: 10,4-81,6) (p=0.007). The rate of adherence was low (29.6%). The leading reasons for non-adherence to treatment were economic (35.6%) and good response (31.4%); for dosage reduction were responsive (62%) and economical (24.6%); for bDMARD discontinuation were due to the effects of the Covid-19 pandemic (40.6%), drug shortage (21.7%) and economy (20.3%); and for drug switching were non-response (30.3%), drug shortage (36.4%), and economical (27.3%). Conclusion: Biologic drugs with IL-6 inhibitors were chosen for the most initiation of treatment and had a longer maintenance time than TNF inhibitors. Adherence rates were low and the main reason for non-adherence was financial incompetence. The main reasons for switching or discontinuing bDMARDs were factors such as financial incompetence, the impact of the Covid-19 pandemic and drug shortages, or non-response with bDMARD.

Article Details

Keywords

Rheumatoid arthritis, biological drugs, reality, Bach Mai Hospital

References

1. Van Vollenhoven RF. Biologics for the Treatment of Rheumatoid Arthritis. Cham: Springer; 2016.
2. Brodszky V, Biro A, Szekanecz Z, et al. Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. Clinicoecon Outcomes Res. 2017;9:139-147.
3. Sullivan E, Kershaw J, Blackburn S, Mahajan P, Boklage SH. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. Rheumatol Ther. 2020.
4. Aaltonen KJ, Joensuu JT, Pirila L, et al. Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland. Scand J Rheumatol. 2016;46(5):359-363.
5. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.
6. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939.
7. Berger N, Peter M, DeClercq J, Choi L, Zuckerman AD. Rheumatoid arthritis medication adherence in a health system specialty pharmacy. The American journal of managed care. 2020;26(12):e380-e387.
8. Rashid N, Lin AT, Aranda G, Jr., et al. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. Journal of medical economics. 2016;19(6):568-575.